Skip to content

Advertisement

  • Review
  • Open Access

Therapy resistance mediated by exosomes

Molecular Cancer201918:58

https://doi.org/10.1186/s12943-019-0970-x

  • Received: 13 November 2018
  • Accepted: 21 February 2019
  • Published:

Abstract

Therapy resistance can arise within tumor cells because of genetic or phenotypic changes (intrinsic resistance), or it can be the result of an interaction with the tumor microenvironment (extrinsic resistance). Exosomes are membranous vesicles 40 to 100 nm in diameter constitutively released by almost all cell types, and mediate cell-to-cell communication by transferring mRNAs, miRNAs, DNAs and proteins causing extrinsic therapy resistance. They transfer therapy resistance by anti-apoptotic signalling, increased DNA-repair or delivering ABC transporters to drug sensitive cells. As functional mediators of tumor-stroma interaction and of epithelial to mesenchymal transition, exosomes also promote environment-mediated therapy resistance.

Exosomes may be used in anticancer therapy exploiting their delivery function. They may effectively transfer anticancer drugs or RNAs in the context of gene therapy reducing immune stimulatory effects of these drugs and hydrophilic qualities facilitating crossing of cell membranes.

Keywords

  • MDR genes
  • Apoptosis
  • Cancer stem cells
  • Immune surveillance
  • Dormancy
  • EMT

Introduction

Tumor therapy resistance is defined as reduction of effectiveness of an antineoplastic therapy. Therapy resistance is one of the major obstacles in cancer treatment. Therapy resistance can arise within tumor cells because of genetic or phenotypic changes (intrinsic resistance), or it can be the result of the tumor microenvironment protecting tumor cells against treatment (extrinsic resistance). Thus, extrinsic resistance arises from the interaction between tumour cells and their surrounding [13]. This extrinsic resistance can even cause changes in gene expression profiles by the exchange of small RNAs, like microRNAs (miRNAs) [4].

Exosomes are nanosized membrane vesicles that constitutively released by almost all cell types. The main physiological role of the exosomes is to mediate cell-cell communication by transferring messenger RNAs (mRNAs), miRNAs, DNAs and proteins (Fig. 1) [1].
Fig. 1
Fig. 1

Exosomal cargo that mediates therapy resistance. Exosomes cause therapy resistance in the recipient cell by transporting DNA, RNA (micro RNA, short interfering RNA), lipids and proteins. They cause decreased apoptosis and anti tumor immunosurveillance and increased DNA repair and stemness in recipient cells. Furthermore they transport multidrug resistance (MDR) transporter to recipient cells or integrate them in reverse orientation in their membrane to decrease intra- and intercellular drug concentration

Exosomes can transport RNAs from one cell to another causing alterations in protein expression of the recipient cell (Fig. 1). Normally RNAs are rapidly cleaved in the blood stream by RNAses [4]. Exosomes protect RNAs from cleavage and allow exchange of RNAs by different cells even over long ranges or different organs [5]. Exosomes reduce hydrophilic qualities of RNAs and therefore facilitate crossing of cell membranes [6].

Furthermore exosomes can mediate therapy resistance by distributing proteins that increase tumor cell survival and DNA repair (Fig. 1) [3]. Exosome signalling generates favourably therapy resistant conditions in the tumor microenvironment and induces the generation of cancer stem cells (CSC) through epithelial-mesenchymal transition (EMT) [7, 8].

Of note, besides the effects of exosomes on recipient cells, exosomes increase therapy resistance of the donor cell by reducing intracellular drug concentrations and by disposing pro-apoptotic proteins like caspases (Fig. 2) [9].
Fig. 2
Fig. 2

Exosomes cause therapy resistance in recipient and donor cells Exosomes transport multi drug resistance (MDR) transporter to recipient cells causing increased efflux of drugs by integrating MDR transporter in the cell membrane. Furthermore, exosomes cause increased anti-apoptotic signaling and DNA repair in the recipient cell. Besides these effects on recipient cells exosomes are important for therapy resistance of the donor cell as well. MDR transporters are incorporated into the exosomal membrane with reverse orientation, which promotes the influx of drugs from the donor cell into the exosome reducing intracellular drug concentration. Exosomes also reduce intracellular concentration of pro-apoptotic signalling factors by transporting them away from the donor cell

The following review summarizes all the mentioned aspects of exosome-mediated therapy resistance of tumor cells. A systematic literature search was performed using PubMed and Cochrane with the combination of the following keywords: “therapy resistance”, “exosomes” and “tumor”.

Tumor therapy resistance through decreased inter- und intracellular drug concentrations

Background

Tumor cells with acquired chemotherapy resistance often display features of multiple drug resistance (MDR). MDR is an insensitivity of cancer cells not only to previously used drugs but also to many other drugs with different chemical structure and mechanism of action [10].

Direct transfer of drug transporters

MDR is associated with increased expression of drug transporters from the adenosine triphosphate (ATP)-binding cassette transporter (ABC) family. These proteins use energy from ATP hydrolysis for active removal of drugs from cells preventing accumulation of anti-cancer drugs [11]. The multidrug resistance protein 1 gene (MDR1, ABCB1) encodes for the most important drug transporter, p-glycoprotein (P-gp). Expression of this protein was noted in over 50% of cancers with MDR phenotype where it can be constitutively expressed or induced by chemotherapy [12]. Approximately 20 different cytotoxic drugs including paclitaxel and doxorubicin are substrates to this transporter. The second most important drug transporter is breast cancer resistant protein (BCRP) encoded by the ABCG2 gene [13].

There is substantial experimental evidence that P-gp and other MDR transporters can be transferred from drug resistant to drug sensitive tumor cells by circulating exosomes [14] causing acquired therapy resistance of the recipient cells in vivo and in vitro (Fig. 2) [1416]. Mechanistically, functional P-gp is incorporated in the exosomal membrane and transferred to donor cells who in return integrate it in their cell surface [14]. Corcoran and colleagues demonstrated in an in vitro model of prostate cancer that MDR1/P-gp is transported via exosomes to docetaxel sensitive cells leading to acquired docetaxel resistance [17]. Drug-sensitive breast cancer cells were shown to acquire a drug-resistant phenotype after exposure to exosomes extracted from a drug resistant cell line. Furthermore, the observed increase in P-gp levels of the recipient cells was proportional to the amount of releases exosomes from drug-resistant cells [18]. In vivo studies of a neuroblastoma xenograft mouse model confirmed this exosomal P-gp transfer and even indicated a higher efficiency of this exosomal transfer under physiological conditions than in cell cultures [15].

Modulation of MDR gene expression by exosomal miRNA/mRNA transfer

Levchenko and colleagues demonstrated that exosomal P-gp transfer led to a prolonged acquired resistant phenotype of tumor cells characterized by the P-gp expression for up to 4 months [15]. The transfer of P-gp alone cannot explain these observed long-term effects, since the half-life of P-gp is approximately 14–17 h [16]. Recent experiments suggested that P-gp-related miRNAs and even mRNAs transferred by exosomes can cause a long-term P-gp expression in the recipient cells [16]. MiR-451 and miR-27a, which are both enriched in exosomes from drug resistant cells [16], upregulate P-gp expression explaining these long-term effects [16, 19]. Furthermore, transcription of exosomal delivered mRNAs contribute to the activation of nuclear factor kappa B (NF-κB), which is known to be involved in the induction of drug resistance by increased MDR1 expression [20].

Reduction of intra- and intercellular drug concentration by exosomes

In addition to their role in conferring therapy resistance to recipient cells, exosomal ABC transporters contribute to drug-resistance of the donor cell by sequestering drugs in exosomes, thereby reducing intracellular drug concentration (Fig. 2). Therefore, P-gp is incorporated into the exosomal membrane with reverse orientation, which promotes the influx of drugs from the donor cell into the exosome [16, 21]. ABCG2-rich exosomes are able to take up riboflavin, topotecan, imidazoacridinone and methotrexate in the same way [22]. Exosomal ABCG2 expression can be induced by the phosphoinositide-3-kinase–protein kinase B (PI3K)- protein kinase B (Akt) signaling pathway and inhibition of this pathway led to cytoplasmic re-localization of ABCG2 and increased drug sensitivity in breast cancer cells [23]. This sequestration of cytotoxic agents appears to be pH dependent as the cisplatin transport into exosomes is increased in an acidic microenvironment [24]. Acidification is common in tumors due to the so-called “Warburg effect” with high extracellular lactate content and inadequate neovascularization [2426]. Additionally, many tumors express H + -ATPases, which pump protons across the plasma membrane and contribute to the acidification of the tumor microenvironment. Basic chemotherapeutic drugs are trapped in the acidic exosomes [25].

Exosomes can also reduce extracellular drug levels by displaying bait targets for therapeutic antibodies on their surface (Fig. 2). Exosomes carry e.g. the cluster of differentiation (CD)-20 receptor, which acts as a bait for therapeutic anti-CD20 antibodies such as rituximab [27]. In breast cancer cells, the human epidermal growth factor receptor-2 (HER2) is found on the surface of exosomes, resulting in the sequestering of the therapeutic monoclonal antibody Herceptin®. Thus, exosomes protect breast cancer cells from antibody-dependent cell-mediated cytotoxicity (ADCC) by NK cells [28]. Advanced breast cancer is associated with increased exosome secretion and increased exosome binding to Herceptin®, suggesting that exosomes facilitate cancer progression by limiting drug availability [28]. Similar results were observed in epithelial cell adhesion molecule (EpCam)-positive breast cancer cells with the EpCam-specific antibody C215 [29].

Tumor therapy resistance through exosome-mediated interference with cell cycle and DNA repair

Background

Exosome-mediated reduction of intracellular and extracellular concentrations of chemotherapeutic agents cannot explain exosome-mediated irradiation resistance. Exosomes can induce irradiation resistance and chemotherapy resistance by influencing cell cycle regulation, apoptosis, and DNA repair of tumor cells [5, 30].

Change in apoptotic homeostasis

Exosomes can shift cellular homeostasis between anti- and pro-apoptotic signals, resulting in increased survival of tumor cells following exposure to DNA-damaging drugs or irradiation. Exosomes can promote tumor cells survival by either decreasing pro-apoptotic signalling in the donor cell or by increasing anti-apoptotic signalling in the recipient cells (Fig. 2) [9, 31].

To promote survival of donor cells, exosomes can reduce intracellular levels of pro-apoptotic proteins shifting the intracellular balance to an anti-apoptotic state [32]. The release of caspase-3 containing exosomes prevented the induction of apoptosis in donor cells. Conversely, the inhibition of this release resulted in an intracellular accumulation of caspase-3 and consequently apoptosis in endothelial donor cells [32].

In recipient cells, exosomes can promote tumor cell survival by three important anti-apoptotic mechanisms:
  1. 1.)

    Exosomes could stimulate recipient cells through surface expressed receptors to induce signal transduction and the activation of anti-apoptotic pathways. In vivo and in vitro studies of multiple myeloma demonstrated that bone-marrow derived exosomes contain high levels of interleukine-6 (IL-6) [33] and this interaction of exosomal IL-6 with multiple myeloma cells inhibited tumor cell apoptosis [2, 33, 34].

     
  2. 2.)

    Exosomes may transfer receptors like CD41 to target cells. CD41 (integrin α-IIb) binds to extracellular matrix, causing integrin-mediated inhibition of apoptosis by preventing anoikis [9, 31, 35].

     
  3. 3.)

    Exosomes could directly transfer transcriptional factors and induce the activation of anti-apoptotic or pro-survival pathways. In a murine model of multiple myeloma, bone marrow derived exosomes inhibit cleavage of full-length caspase 3 and 9 and consequently apoptosis. Furthermore they promoted tumor cell survival via inhibition of the c-Jun N-terminal kinase (JNK) pathway. This led to Bortezomib resistance [31]. Other involved anti-apoptotic signalling pathways in exosome mediated therapy resistance are p38, p53, JNK, Rapidly Accelerated Fibrosarcoma (Raf)/ Mitogen-activated protein kinase kinase (MEK)/ extracellular signal–regulated kinases (ERK) and Akt [9, 31, 36].

     

Anti-apoptotic signalling mediated by miRNA

Exosomes can confer resistance to therapy-sensitive tumor cells by transmitting miRNAs that alter cell cycle control and induce anti-apoptotic programs (Fig. 1). MiRNAs are small, non-coding RNAs with a length of 18 to 24 nucleotides that control gene expression posttranscriptionally [37]. They accumulate in exosomes where they are protected from cleavage by RNAses in the blood [4]. Tumor exosomes do not only transport RNAs but can even modify miRNAs to e.g. induce tumor progression in breast cancer and perform cell-independent miRNA synthesis [38]. Chen and colleagues demonstrated miR-222 was upregulated in exosomes from drug resistant breast cancer cells. MiR-222 conferred this resistance to drug sensitive cells by down regulation of the Phosphatase and tensin homolog (PTEN) pathway, which promotes cell cycle arrest [39].

Furthermore, exosomes can increase therapy resistance of the donor cell by decreasing intracellular levels of tumor suppressive miRNAs [40]. The release of exosomes containing tumor-suppressive miR-145/−34a from colorectal cancer cells led to increased 5-fluoruracil resistance of these cells by decreased apoptosis [40].

MiRNA research is challenging because every miRNA influences different pathways by transcriptional regulation and there are thousand different variants. To help understand circulatory miRNAs and their function, databases such as miRandola were developed [41]. The miRandola database contains 3282 entries to date in total and 1106 entries about exosomal mi-RNA. Besides miRNA, this database classifies extracellular circulating RNAs like long non-coding RNA (lncRNA) and circular RNA (circRNA). The miRandola is available online at: http://mirandola.iit.cnr.it/index.php.

A selection of important miRNAs involved in exosomal mediated therapy resistance is summarized in Table 1.
Table 1

Exosomal miRNAs involved in therapy response

miRNA

Effects

Cancer type

Reference

Pro-oncogenic

 miR-222

PTEN inhibition- > anti-apoptotic

p27/kip inhibition- > cell cycle progression

breast cancer

gastric cancer

non-small lung cancer

hepatocellular carcinoma

[104108]

 miR-485-3p

increased transcription of topoisomerase IIα, multidrug resistance gene 1, cyclin B2- > increased survival, drug resistance, DNA repair

prostate cancer

rhabdomyosarcoma

lymphoblastic leukemia

[109, 110]

 miR-100

interference with HIF1α signalling

anti-apoptotic

breast cancer

melanoma

[39, 111]

 miR-23a

activation of MAPK signalling/inhibition of Sprouty2- > therapy resistance, migration, invasion

breast cancer

[39, 112]

Anti-oncogenic

 miR-145

growth inhibition- > down-regulation of c-myc and Erk5

colorectal cancer

B-cell lymphomas

gastric cancer

[40, 113116]

 miR-34a

pro-apoptotic

inhibition of cKit/ stemness markers (CD44, BMI-1)

colorectal cancer

prostate cancer

[117119]

 let 7 a-c

regulates RAS oncogene

lung cancer

breast cancer

[108, 120123]

 miR-15/16

inhibition of bcl2/ CDK1/CDK2 expression

leukemia (CLL)

prostate cancer

[123125]

DNA repair

Exosomes can promote tumor cell survival after genotoxic stress like irradiation by triggering DNA repair. After exposure to irradiation, breast cancer exosomes led to an increased phosphorylation of ataxia telangiectasia mutated (ATM), Histone H2AX and checkpoint kinase 1 (Chk1) in recipient cells indicating the induction of DNA damage repair responses [42]. In an in vitro model of head and neck cancer, tumor derived exosomes were able to increase radioresistance in neighbouring cells by induction of DNA double strand break repair. Furthermore, irradiated tumor cells released more exosomes than un-irradiated cells [43, 44]. Destabilization of the exosomes decreased radioresistance and DNA double strand break repair in recipient cells [44]. As the treatment with RNAse abrogated the exosomal effect on radioresistance, the authors concluded that RNA, especially miRNA, might mediate the observed effect of exosomes on radioresistance [44]. This highlights again the outstanding importance of exosomes for RNA signalling. Interestingly, irradiated cells also take up exosomes more effectively by co-localizing CD29 and CD81 [43].

Exosomes can further increase radiation resistance by promoting cell migration causing cancer cells to leave the irradiated area. In glioblastoma cells, Arscott and colleagues observed that radiation affects the molecular composition of exosomes to adopt a migratory phenotype [45].

Exosomes and tumor immune escape mechanism

Tumor cells carry molecules on their surface that can be detected by the immune system, known as tumor antigens. Tumor antigens stimulate the immune system of the patient toward an anti-tumor immune response. This fact is exploited by cancer immunotherapy, which aims at increasing patients’ anti-tumor immune response. Especially immune checkpoint inhibitors, like programmed death-ligand 1 (PD-L1) or chemokine receptor type 4 (CXCR4)-inhibitors, and targeted antibodies are under current scientific focus [46]. For successful tumor progression, tumors need to develop immune resistance mechanisms. Exosomes can inhibit tumor immune response and limit the effectiveness of immunotherapy (Fig. 3) [47, 48].
Fig. 3
Fig. 3

Exosomes and tumor immunosurveillance. Exosome reduce tumor immunosurveillance by interfering with the innate and adaptive immune system. This can cause failure of tumor immunotherapy. Exosomes reduce antibody dependent cytotoxicity by inhibiting natural killer cells. Exosomes reduce activation of the complement systems causing reduced membrane attack complex (MAC) formation and cell lysis. Both mechanism are important effector functions of therapeutic antibodies. Furthermore exosomes reduce T- and B-lymphocyte function and their differentiation from progenitor cells. Lymphocyte function is important for the vaccine effect of therapeutic antibodies

Innate immune system (NK cells, complement)

Natural killer (NK) cells are key players in antibody dependent cell-mediated cytotoxicity (ADCC) which is suggested as key effector function of therapeutic antibodies [49]. Tumor derived exosomes inhibit NK cell function by decreasing perforin expression and NK cell proliferation (Fig. 3). Exosomes inhibit NK cell cycle progression through Janus kinase 3 (Jak3) and cyclin D1 blockade [50] or via transforming growth factor- β1 (TGF-β1) signalling [51]. Another mechanism of monoclonal antibody therapies is the activation of the complement systems causing membrane attack complex (MAC) formation and cell lysis [52]. Tumor-derived exosomes were demonstrated to contain protein kinase casein kinase 2 (CK2) which phosphorylated complement C9 and protected B-lymphoma cells from complement-mediated lysis [53]. Furthermore, tumor cells can protect themselves from complement-mediated lysis by shedding MACs from their plasma membrane via exosomes [54, 55].

Adaptive immune system

Lymphocyte effector function can be impaired by treatment with tumor exosomes from different cancer cells. These tumor exosomes reduced production of Interferon-γ and impaired cytotoxic CD8+ T-lymphocyte function [51]. Tumor derived exosomes express the T-cell apoptosis-inducing molecule Fas Ligand (FasL) in vivo and in vitro causing apoptosis of cytotoxic CD8+ T-lymphocytes [5660]. Besides that, exosomes impair the adaptive immune system by promotion of regulatory T-cell proliferation via TGF-β1 and interleukin-10 (IL-10) at the expense of other T cell subsets [61, 62].

Tumor derived exosomes inhibit differentiation of bone marrow derived progenitor cells to dendritic cells impairing tumor antigen presentation and consequently further T- and B-cell activation [63].

So far, it has been thought that therapeutic antibodies destroy tumor cells by innate immune-effector mechanisms. More recently, it has been observed that therapeutic antibodies can induce long lasting tumor adaptive immunity, which could be responsible for sustained clinical responses. This effect has been termed the vaccine effect of antibodies. It is believed that this effect is caused by the induction of an adaptive immune memory response via T- and B-lymphocytes (Fig. 3) [64]. Exosomes may interfere with this therapeutic adaptive immune response by affecting T- and B- lymphocyte function as well as antigen presentation [65].

Exosomes and cancer stem cells

Cancer stem cells and dormancy

Chemotherapy and irradiation are mainly effective against proliferating cells. Tumor cells may enter a quiescent state and thus evade antineoplastic treatment [66]. Cellular dormancy means that cells are recruited in to the G0-phase of the cell cycle but remain capable of cell division in response to mitotic stimulation. Dormancy might also critically contribute to early stages of tumor development and the formation of clinically undetectable metastatic foci [66]. Stroma-derived exosomes induced dormancy in breast cancer cells in vitro and in vivo and this dormancy was associated with an increased carboplatin resistance. This effect was mediated by miR-222/223 and blocking of these miRNAs abrogated dormancy and the associated carboplatin resistance [67].

Cellular dormancy is a typical feature of stem cells to maintain tissue homeostasis. In this context, cancer stem cells (CSC) are of particular interest [68]. There is a multitude of literature that stem cells, especially mesenchymal stem cells, can induce drug resistance in tumor cells [69, 70]. Exosomes can induce a CSC like phenotype in tumor cells (Fig. 4) [71]. In an in vitro model of diffuse large cell B cell lymphoma exosomes induced a CSC like phenotype and dormancy through Wingless-related integration site (Wnt)-signalling. These cells expelled doxorubicin more effectively than non-CSC [72]. Boelens and colleagues demonstrated in an in vitro and in vivo model of breast cancer that fibroblast derived exosomes induce a CSC like phenotype in breast cancer cells by Neurogenic locus notch homolog protein 3 (Notch3)/ Signal transducer and activator of transcription 1 (STAT1) signalling which is associated with radiochemotherapy resistance [73]. Exosomal IL-6, Activin-A and granulocyte colony stimulating factor (G-CSF) induced de-differentiation of lung carcinoma cells to a more CSC-like phenotype and reduced cell cycle progression, which was associated with higher methotrexate resistance [74]. Besides promoting CSC-like phenotypes and dormancy in cancer cells, exosomes from fibroblasts can reverse this dormant phenotype by transferring mitochondrial DNA and inducing oxidative phosphorylation allowing recurrence of the disease and metastasis [75].
Fig. 4
Fig. 4

Exosomes, cancer stem cells and EMT. Exosomes induce a cancer stem cell (CSC)-like phenotype in tumor cells through epithelial to mesenchymal transition (EMT). CSC are considered therapy resistant by increased drug efflux capacities and increased DNA repair. A key feature of CSC is their ability to become dormant and thus evade therapy, which is manly effective against proliferating cells. Cellular dormancy means that cells are recruited in to the G0-phase of the cell cycle but remain capable of cell division in response to mitotic stimulation. After therapy CSC can cause repopulation of the tumor mass under the influence of exosomes by undergoing mesenchymal to epithelial transition (MET)

Epithelial–mesenchymal transition (EMT)

The acquisition of a CSC like phenotype is closely linked to EMT (Fig. 4) [76]. CSCs may originate from epithelial cells undergoing EMT, a process characterized by loss of E-cadherin expression. EMT is enabled by transcriptional repressors such as SNAIL and SLUG. These events are accompanied by an increase of stemness-related transcription factors, B lymphoma Moloney murine leukemia virus insertion region 1 homolog (BMI1) and enhancer of zeste homolog 2 (EZH2), which may trigger the transformation of epithelial cells into mesenchymal state with the ability to invade other tissues and increased therapy resistance [7779]. Exosomes are regarded important mediators of these phenotypic changes and tumor stroma interaction [71, 80]. EMT mediates therapy resistance by induction of a dormant, CSC like phenotype [76, 81] and by interaction with anti-apoptotic pathways and DNA repair [79, 82]. Tumor-derived exosomes can force other cancer cells to acquire a mesenchymal phenotype [83]. Exosome-depleted cancer cells failed to gain a stroma-mediated growth advantage, and EMT, mediated by exosomal TGF-β1, was significantly impaired in these cells [84]. Exosomal miR-155 is linked to the development of drug resistance in breast cancer [85, 86]. MiR-155 is also closely involved with TGF-β-induced EMT, invasion, and metastasis demonstrating the link between EMT, CSC, exosomes and therapy resistance [87, 88]. This is supported by the finding of increased CSC markers in tumor biopsies from patients with breast cancer after treatment with chemotherapy for 12 weeks [89].

Exosomes as therapeutic tumor approach

Despite all the challenges associated with the exosome use for successful cancer treatment, they can also be exploited for the development of new therapeutic techniques.Exosomes may serve for delivery of anticancer drugs or the transfer of RNAs in the context of gene therapy [80]. As exosomes naturally carry RNA between cells, these particles might be useful in gene cancer therapy to deliver therapeutic RNAs, like short interfering RNA (siRNA) or miRNA to target cells. Normally, exogenous RNA is prone to degradation via RNAse, has a limited ability to cross cell membranes due to the negative charged surface and may induce an immune response. Exosomes can overcome these limitations of RNA based therapies [6]. Other advantages of exosomes are their biocompatibility, non-cytotoxicity, low immunogenity and that they are simple to produce, easy to store, have a long life span, and high cargo loading capacity [9092]. Their small size enables exosomes to easily escape from lung clearance and pass through the blood-brain barrier [93, 94]. Exosomes further enable specific targeting of tumor cells or CSC via surface receptors reducing negative side effects on healthy tissue [92]. These characteristics together make exosomes a promising drug carrier for cancer treatment [92].

Exosomes from mesenchymal stem cells (MSC) can be transfected with synthetic miRNAs. These exosomes reduce chemotherapy resistance [95]. Lou and colleagues transfected adipose tissue-derived MSCs with miR-122. This miR-122 was secreted with exosomes and increased chemotherapy sensitivity of hepatocellular carcinoma cells [96]. Furthermore, MSC can transfer anti-miR-9 via exosomes to glioblastoma cells. The delivery of anti-miR-9 to the drug resistant glioblastoma cells reversed the expression of multidrug transporters and sensitized glioblastoma cells to temzolomid, as shown by increased cell death and caspase activity [97]. MiR-143 can be transferred via exosomes from MSC to osteosarcoma cells suppressing their migratory abilities [95].

In a murine sarcoma model, mice were treated with exosomes containing TGF-β1-siRNA. These exosomes strongly suppressed TGF-β1 expression and signaling in the recipient tumor cells, and thus inhibited the growth of the tumor cells and the development of lung metastases [98].

Furthermore, MSC are able to deliver conventional chemotherapeutics like Paclitaxel to tumor cells via exosomes. Pascucci and collegues demonstrated that MSC loaded with paclitaxel secrete a significant amount of paclitaxel in exosomes. The paclitaxel-containing exosomes possess strong anti-proliferative effects on human pancreatic cells [99]. Paclitaxel loaded exosomes have 50 times more cytotoxicity than free paclitaxel for drug resistant cancer cells in vitro [100, 101]. They can also reduce metastases and tumor size in a mouse model of lung carcinoma. The authors concluded that exosome-encapsulated paclitaxel might directly target drug resistant CSCs [100].

Most research on exosome-based therapy has been performed in vitro or in mouse models. However there are already a few clinical trials using exosomes. A phase I trial showed that exosomes loaded with tumor antigens were able to activate immune response and disease progression was slowed in a small number of non-small cell lung cancer patients [102]. A phase II trial was performed which showed that IFN-γ-loaded exosomes were capable of boosting NK cell-mediated anti-tumor immunity in advanced non-small cell lung cancer patients. Thirty two percent (7/22) of participants experienced stabilization for more than 4 months [103].

Conclusion

Exosomes are functional mediators of tumor stroma interaction and play a fundamental role in every mentioned category of tumor therapy resistance.

Exosomes can mediate therapy resistance by direct drug export, intracellular reduction of drugs and by the transport of drug efflux pumps. Exosomes can shift cellular homeostasis between anti- and pro-apoptotic signalling resulting in increased tumor cell survival after exposure to DNA damaging chemotherapeutic drugs or irradiation and increase DNA repair. Moreover, exosome signaling generates therapy resistant conditions in the tumor microenvironment and induces cancer stem cell like phenotypes through EMT in tumor cells leading to environment-mediated drug resistance.

Abbreviations

ABC transporter: 

ATP-binding cassette transporter

ADCC: 

Antibody dependent cellular cytotoxicity

CD: 

Cluster of differentiation

CSC: 

Cancer stem cell

EMT: 

Epithelial to mesenchymal transition

MDR genes: 

Multidrug resistance genes

miRNA (miR): 

micro RNA

mRNA: 

messenger RNA

MSC: 

Mesenchymal stem cell

NK cells: 

Natural killer cells

P-gp: 

P-glycoprotein

TGF-β1: 

Tumor growth factor-β1

Declarations

Acknowledgements

Mr. Peter Bauer helped to design all figures.

Funding

This study was supported by Austrian Science Fund (FWF, P29457), Anniversary Fund of Austrian National Bank (ÖNB 17620), and Ingrid Shaker-Nessmann Cancer Research Foundation.

Availability of data and materials

Not applicable

Authors’ contributions

TBS analyzed and interpreted the scientific data and was a major contributor in writing the manuscript. SS, JD, HR, IS revised the manuscript and contributed in writing the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Innsbruck, Innsbruck, Austria
(2)
Laboratory for Experimental and Translational Research on Radiation Oncology (EXTRO-Lab), Department of Therapeutic Radiology and Oncology, Medical University of Innsbruck, Anichstr. 35, A-6020 Innsbruck, Austria
(3)
EXTRO-Lab, Tyrolean Cancer Research Institute, Innsbruck, Austria

References

  1. Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009;9(9):665–74.PubMedView ArticlePubMed CentralGoogle Scholar
  2. Hazlehurst LA, Dalton WS. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev. 2001;20(1–2):43–50.PubMedView ArticlePubMed CentralGoogle Scholar
  3. Guan J, Chen J. Mesenchymal stem cells in the tumor microenvironment. Biomed Rep. 2013;1(4):517–21.PubMedPubMed CentralView ArticleGoogle Scholar
  4. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–9.View ArticleGoogle Scholar
  5. Steinbichler TB, Dudas J, Riechelmann H, Skvortsova II. The role of exosomes in cancer metastasis. Semin Cancer Biol. 2017;44:170–81.View ArticleGoogle Scholar
  6. Shtam TA, Kovalev RA, Varfolomeeva EY, Makarov EM, Kil YV, Filatov MV. Exosomes are natural carriers of exogenous siRNA to human cells in vitro. Cell Commun Signal. 2013;11:88.PubMedPubMed CentralView ArticleGoogle Scholar
  7. Bach DH, Hong JY, Park HJ, Lee SK. The role of exosomes and miRNAs in drug-resistance of cancer cells. Int J Cancer. 2017;141(2):220–30.PubMedView ArticlePubMed CentralGoogle Scholar
  8. Sharma A. Chemoresistance in cancer cells: exosomes as potential regulators of therapeutic tumor heterogeneity. Nanomedicine (London). 2017;12(17):2137–48.View ArticleGoogle Scholar
  9. Camussi G, Deregibus MC, Bruno S, Grange C, Fonsato V, Tetta C. Exosome/microvesicle-mediated epigenetic reprogramming of cells. Am J Cancer Res. 2011;1(1):98–110.PubMedPubMed CentralGoogle Scholar
  10. Ullah MF. Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. Asian Pac J Cancer Prev. 2008;9(1):1–6.PubMedPubMed CentralGoogle Scholar
  11. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist. 2003;8(5):411–24.PubMedView ArticlePubMed CentralGoogle Scholar
  12. Moitra K, Lou H, Dean M. Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin Pharmacol Ther. 2011;89(4):491–502.PubMedView ArticlePubMed CentralGoogle Scholar
  13. Januchowski R, Sterzynska K, Zaorska K, Sosinska P, Klejewski A, Brazert M, et al. Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines. J Ovarian Res. 2016;9(1):65.PubMedPubMed CentralView ArticleGoogle Scholar
  14. Bebawy M, Combes V, Lee E, Jaiswal R, Gong J, Bonhoure A, et al. Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells. Leukemia. 2009;23(9):1643–9.View ArticleGoogle Scholar
  15. Levchenko A, Mehta BM, Niu X, Kang G, Villafania L, Way D, et al. Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells. Proc Natl Acad Sci U S A. 2005;102(6):1933–8.PubMedPubMed CentralView ArticleGoogle Scholar
  16. Sousa D, Lima RT, Vasconcelos MH. Intercellular transfer of cancer drug resistance traits by extracellular vesicles. Trends Mol Med. 2015;21(10):595–608.PubMedView ArticlePubMed CentralGoogle Scholar
  17. Corcoran C, Rani S, O'Brien K, O'Neill A, Prencipe M, Sheikh R, et al. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS One. 2012;7(12):e50999.PubMedPubMed CentralView ArticleGoogle Scholar
  18. Lv MM, Zhu XY, Chen WX, Zhong SL, Hu Q, Ma TF, et al. Exosomes mediate drug resistance transfer in MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein. Tumour Biol. 2014;35(11):10773–9.PubMedView ArticlePubMed CentralGoogle Scholar
  19. An X, Sarmiento C, Tan T, Zhu H. Regulation of multidrug resistance by microRNAs in anti-cancer therapy. Acta Pharm Sin B. 2017;7(1):38–51.PubMedView ArticlePubMed CentralGoogle Scholar
  20. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, et al. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene. 2003;22(1):90–7.PubMedView ArticlePubMed CentralGoogle Scholar
  21. Gong J, Luk F, Jaiswal R, George AM, Grau GE, Bebawy M. Microparticle drug sequestration provides a parallel pathway in the acquisition of cancer drug resistance. Eur J Pharmacol. 2013;721(1–3):116–25.PubMedView ArticlePubMed CentralGoogle Scholar
  22. Goler-Baron V, Assaraf YG. Structure and function of ABCG2-rich extracellular vesicles mediating multidrug resistance. PLoS One. 2011;6(1):e16007.PubMedPubMed CentralView ArticleGoogle Scholar
  23. Goler-Baron V, Sladkevich I, Assaraf YG. Inhibition of the PI3K-Akt signaling pathway disrupts ABCG2-rich extracellular vesicles and overcomes multidrug resistance in breast cancer cells. Biochem Pharmacol. 2012;83(10):1340–8.PubMedView ArticlePubMed CentralGoogle Scholar
  24. Federici C, Petrucci F, Caimi S, Cesolini A, Logozzi M, Borghi M, et al. Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin. PLoS One. 2014;9(2):e88193.PubMedPubMed CentralView ArticleGoogle Scholar
  25. De Milito A, Fais S. Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol. 2005;1(6):779–86.PubMedView ArticlePubMed CentralGoogle Scholar
  26. Safaei R, Larson BJ, Cheng TC, Gibson MA, Otani S, Naerdemann W, et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther. 2005;4(10):1595–604.View ArticleGoogle Scholar
  27. Aung T, Chapuy B, Vogel D, Wenzel D, Oppermann M, Lahmann M, et al. Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proc Natl Acad Sci U S A. 2011;108(37):15336–41.PubMedPubMed CentralView ArticleGoogle Scholar
  28. Ciravolo V, Huber V, Ghedini GC, Venturelli E, Bianchi F, Campiglio M, et al. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol. 2012;227(2):658–67.PubMedPubMed CentralView ArticleGoogle Scholar
  29. Battke C, Ruiss R, Welsch U, Wimberger P, Lang S, Jochum S, et al. Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC. Cancer Immunol Immunother. 2011;60(5):639–48.PubMedView ArticlePubMed CentralGoogle Scholar
  30. Kalluri R. The biology and function of exosomes in cancer. J Clin Invest. 2016;126(4):1208–15.PubMedPubMed CentralView ArticleGoogle Scholar
  31. Wang J, Hendrix A, Hernot S, Lemaire M, De Bruyne E, Van Valckenborgh E, et al. Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood. 2014;124(4):555–66.PubMedView ArticlePubMed CentralGoogle Scholar
  32. Boing AN, Stap J, Hau CM, Afink GB, Ris-Stalpers C, Reits EA, et al. Active caspase-3 is removed from cells by release of caspase-3-enriched vesicles. Biochim Biophys Acta. 2013;1833(8):1844–52.PubMedView ArticlePubMed CentralGoogle Scholar
  33. Xu FH, Sharma S, Gardner A, Tu Y, Raitano A, Sawyers C, et al. Interleukin-6-induced inhibition of multiple myeloma cell apoptosis: support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway. Blood. 1998;92(1):241–51.PubMedPubMed CentralGoogle Scholar
  34. Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest. 2013;123(4):1542–55.PubMedPubMed CentralView ArticleGoogle Scholar
  35. Boudreau N, Werb Z, Bissell MJ. Suppression of apoptosis by basement membrane requires three-dimensional tissue organization and withdrawal from the cell cycle. Proc Natl Acad Sci U S A. 1996;93(8):3509–13.PubMedPubMed CentralView ArticleGoogle Scholar
  36. Manier S, Sacco A, Leleu X, Ghobrial IM, Roccaro AM. Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol. 2012;2012:157496.PubMedPubMed CentralView ArticleGoogle Scholar
  37. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(7):522–31.PubMedView ArticlePubMed CentralGoogle Scholar
  38. Melo SA, Sugimoto H, O'Connell JT, Kato N, Villanueva A, Vidal A, et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell. 2014;26(5):707–21.PubMedPubMed CentralView ArticleGoogle Scholar
  39. Chen WX, Cai YQ, Lv MM, Chen L, Zhong SL, Ma TF, et al. Exosomes from docetaxel-resistant breast cancer cells alter chemosensitivity by delivering microRNAs. Tumour Biol. 2014;35(10):9649–59.PubMedPubMed CentralView ArticleGoogle Scholar
  40. Akao Y, Khoo F, Kumazaki M, Shinohara H, Miki K, Yamada N. Extracellular disposal of tumor-suppressor miRs-145 and -34a via microvesicles and 5-FU resistance of human colon cancer cells. Int J Mol Sci. 2014;15(1):1392–401.PubMedPubMed CentralView ArticleGoogle Scholar
  41. Russo F, Di Bella S, Nigita G, Macca V, Lagana A, Giugno R, et al. miRandola: extracellular circulating microRNAs database. PLoS One. 2012;7(10):e47786.PubMedPubMed CentralView ArticleGoogle Scholar
  42. Dutta S, Warshall C, Bandyopadhyay C, Dutta D, Chandran B. Interactions between exosomes from breast cancer cells and primary mammary epithelial cells leads to generation of reactive oxygen species which induce DNA damage response, stabilization of p53 and autophagy in epithelial cells. PLoS One. 2014;9(5):e97580.PubMedPubMed CentralView ArticleGoogle Scholar
  43. Hazawa M, Tomiyama K, Saotome-Nakamura A, Obara C, Yasuda T, Gotoh T, et al. Radiation increases the cellular uptake of exosomes through CD29/CD81 complex formation. Biochem Biophys Res Commun. 2014;446(4):1165–71.PubMedView ArticlePubMed CentralGoogle Scholar
  44. Mutschelknaus L, Peters C, Winkler K, Yentrapalli R, Heider T, Atkinson MJ, et al. Exosomes derived from squamous head and neck Cancer promote cell survival after ionizing radiation. PLoS One. 2016;11(3):e0152213.PubMedPubMed CentralView ArticleGoogle Scholar
  45. Arscott WT, Tandle AT, Zhao S, Shabason JE, Gordon IK, Schlaff CD, et al. Ionizing radiation and glioblastoma exosomes: implications in tumor biology and cell migration. Transl Oncol. 2013;6(6):638–48.PubMedPubMed CentralView ArticleGoogle Scholar
  46. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.PubMedPubMed CentralView ArticleGoogle Scholar
  47. Ichim TE, Zhong Z, Kaushal S, Zheng X, Ren X, Hao X, et al. Exosomes as a tumor immune escape mechanism: possible therapeutic implications. J Transl Med. 2008;6:37.PubMedPubMed CentralView ArticleGoogle Scholar
  48. Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol. 2009;9(8):581–93.PubMedView ArticlePubMed CentralGoogle Scholar
  49. Seidel UJ, Schlegel P, Lang P. Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol. 2013;4:76.PubMedPubMed CentralView ArticleGoogle Scholar
  50. Liu C, Yu S, Zinn K, Wang J, Zhang L, Jia Y, et al. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol. 2006;176(3):1375–85.View ArticleGoogle Scholar
  51. Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z. Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol. 2008;180(11):7249–58.PubMedView ArticleGoogle Scholar
  52. Rogers LM, Veeramani S, Weiner GJ. Complement in monoclonal antibody therapy of cancer. Immunol Res. 2014;59(1–3):203–10.PubMedPubMed CentralView ArticleGoogle Scholar
  53. Bohana-Kashtan O, Pinna LA, Fishelson Z. Extracellular phosphorylation of C9 by protein kinase CK2 regulates complement-mediated lysis. Eur J Immunol. 2005;35(6):1939–48.PubMedView ArticleGoogle Scholar
  54. Pilzer D, Fishelson Z. Mortalin/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis. Int Immunol. 2005;17(9):1239–48.PubMedView ArticleGoogle Scholar
  55. Scolding NJ, Morgan BP, Houston WA, Linington C, Campbell AK, Compston DA. Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature. 1989;339(6226):620–2.PubMedView ArticleGoogle Scholar
  56. Abusamra AJ, Zhong Z, Zheng X, Li M, Ichim TE, Chin JL, et al. Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis. Blood Cells Mol Dis. 2005;35(2):169–73.View ArticleGoogle Scholar
  57. Andreola G, Rivoltini L, Castelli C, Huber V, Perego P, Deho P, et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med. 2002;195(10):1303–16.PubMedPubMed CentralView ArticleGoogle Scholar
  58. Taylor DD, Gercel-Taylor C, Lyons KS, Stanson J, Whiteside TL. T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res. 2003;9(14):5113–9.PubMedGoogle Scholar
  59. Huber V, Fais S, Iero M, Lugini L, Canese P, Squarcina P, et al. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology. 2005;128(7):1796–804.PubMedPubMed CentralView ArticleGoogle Scholar
  60. Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res. 2005;11(3):1010–20.PubMedPubMed CentralGoogle Scholar
  61. Szajnik M, Czystowska M, Szczepanski MJ, Mandapathil M, Whiteside TL. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One. 2010;5(7):e11469.PubMedPubMed CentralView ArticleGoogle Scholar
  62. Wieckowski EU, Visus C, Szajnik M, Szczepanski MJ, Storkus WJ, Whiteside TL. Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol. 2009;183(6):3720–30.PubMedPubMed CentralView ArticleGoogle Scholar
  63. Yu S, Liu C, Su K, Wang J, Liu Y, Zhang L, et al. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol. 2007;178(11):6867–75.PubMedView ArticleGoogle Scholar
  64. Deligne C, Milcent B, Josseaume N, Teillaud JL, Siberil S. Impact of depleting therapeutic monoclonal antibodies on the host adaptive immunity: a Bonus or a Malus? Front Immunol. 2017;8:950.PubMedPubMed CentralView ArticleGoogle Scholar
  65. Dorsam B, Reiners KS, von Strandmann EP. Cancer-derived extracellular vesicles: friend and foe of tumour immunosurveillance. Philos Trans R Soc Lond Ser B Biol Sci. 2018;373(1737):20160481.View ArticleGoogle Scholar
  66. Kleffel S, Schatton T. Tumor dormancy and cancer stem cells: two sides of the same coin? Adv Exp Med Biol. 2013;734:145–79.PubMedView ArticleGoogle Scholar
  67. Bliss SA, Sinha G, Sandiford OA, Williams LM, Engelberth DJ, Guiro K, et al. Mesenchymal stem cell-derived exosomes stimulate cycling quiescence and early breast cancer dormancy in bone marrow. Cancer Res. 2016;76(19):5832–44.PubMedPubMed CentralView ArticleGoogle Scholar
  68. Kusumbe AP, Bapat SA. Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res. 2009;69(24):9245–53.PubMedView ArticleGoogle Scholar
  69. Ji R, Zhang B, Zhang X, Xue J, Yuan X, Yan Y, et al. Exosomes derived from human mesenchymal stem cells confer drug resistance in gastric cancer. Cell Cycle. 2015;14(15):2473–83.PubMedPubMed CentralView ArticleGoogle Scholar
  70. Roodhart JM, Daenen LG, Stigter EC, Prins HJ, Gerrits J, Houthuijzen JM, et al. Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell. 2011;20(3):370–83.PubMedView ArticleGoogle Scholar
  71. Akhter MZ, Sharawat SK, Kumar V, Kochat V, Equbal Z, Ramakrishnan M, et al. Aggressive serous epithelial ovarian cancer is potentially propagated by EpCAM(+)CD45(+) phenotype. Oncogene. 2018;37(16):2089–103.PubMedView ArticleGoogle Scholar
  72. Koch R, Demant M, Aung T, Diering N, Cicholas A, Chapuy B, et al. Populational equilibrium through exosome-mediated Wnt signaling in tumor progression of diffuse large B-cell lymphoma. Blood. 2014;123(14):2189–98.PubMedView ArticleGoogle Scholar
  73. Boelens MC, Wu TJ, Nabet BY, Xu B, Qiu Y, Yoon T, et al. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell. 2014;159(3):499–513.PubMedPubMed CentralView ArticleGoogle Scholar
  74. Rodrigues CFD, Serrano E, Patricio MI, Val MM, Albuquerque P, Fonseca J, et al. Stroma-derived IL-6, G-CSF and Activin-A mediated dedifferentiation of lung carcinoma cells into cancer stem cells. Sci Rep. 2018;8(1):11573.PubMedPubMed CentralView ArticleGoogle Scholar
  75. Sansone P, Savini C, Kurelac I, Chang Q, Amato LB, Strillacci A, et al. Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy in hormonal therapy-resistant breast cancer. Proc Natl Acad Sci U S A. 2017;114(43):E9066–E75.PubMedPubMed CentralView ArticleGoogle Scholar
  76. Steinbichler TB, Dudas J, Skvortsov S, Ganswindt U, Riechelmann H, Skvortsova II. Therapy resistance mediated by cancer stem cells. Semin Cancer Biol. 2018;53:156–67.PubMedView ArticleGoogle Scholar
  77. Dave B, Mittal V, Tan NM, Chang JC. Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res. 2012;14(1):202.PubMedPubMed CentralView ArticleGoogle Scholar
  78. Dudas J, Bitsche M, Schartinger V, Falkeis C, Sprinzl GM, Riechelmann H. Fibroblasts produce brain-derived neurotrophic factor and induce mesenchymal transition of oral tumor cells. Oral Oncol. 2011;47(2):98–103.PubMedPubMed CentralView ArticleGoogle Scholar
  79. Steinbichler TB, Alshaimaa A, Maria MV, Daniel D, Herbert R, Jozsef D, et al. Epithelial-mesenchymal crosstalk induces radioresistance in HNSCC cells. Oncotarget. 2018;9(3):3641–52.PubMedView ArticleGoogle Scholar
  80. Fu H, Yang H, Zhang X, Xu W. The emerging roles of exosomes in tumor-stroma interaction. J Cancer Res Clin Oncol. 2016;142(9):1897–907.PubMedPubMed CentralView ArticleGoogle Scholar
  81. Mitra A, Mishra L, Li S. EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget. 2015;6(13):10697–711.PubMedPubMed CentralView ArticleGoogle Scholar
  82. Steinbichler TB, Metzler V, Pritz C, Riechelmann H, Dudas J. Tumor-associated fibroblast-conditioned medium induces CDDP resistance in HNSCC cells. Oncotarget. 2016;7(3):2508–18.Google Scholar
  83. Webber J, Steadman R, Mason MD, Tabi Z, Clayton A. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res. 2010;70(23):9621–30.View ArticleGoogle Scholar
  84. Webber JP, Spary LK, Sanders AJ, Chowdhury R, Jiang WG, Steadman R, et al. Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes. Oncogene. 2015;34(3):290–302.PubMedPubMed CentralView ArticleGoogle Scholar
  85. Santos JC, Lima NDS, Sarian LO, Matheu A, Ribeiro ML, Derchain SFM. Exosome-mediated breast cancer chemoresistance via miR-155 transfer. Sci Rep. 2018;8(1):829.PubMedPubMed CentralView ArticleGoogle Scholar
  86. Shen R, Wang Y, Wang CX, Yin M, Liu HL, Chen JP, et al. MiRNA-155 mediates TAM resistance by modulating SOCS6-STAT3 signalling pathway in breast cancer. Am J Transl Res. 2015;7(10):2115–26.PubMedPubMed CentralGoogle Scholar
  87. Johansson J, Berg T, Kurzejamska E, Pang MF, Tabor V, Jansson M, et al. MiR-155-mediated loss of C/EBPbeta shifts the TGF-beta response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer. Oncogene. 2013;32(50):5614–24.PubMedPubMed CentralView ArticleGoogle Scholar
  88. Liu F, Kong X, Lv L, Gao J. TGF-beta1 acts through miR-155 to down-regulate TP53INP1 in promoting epithelial-mesenchymal transition and cancer stem cell phenotypes. Cancer Lett. 2015;359(2):288–98.PubMedView ArticlePubMed CentralGoogle Scholar
  89. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol. 2005;23(6):1169–77.PubMedView ArticlePubMed CentralGoogle Scholar
  90. Munagala R, Aqil F, Jeyabalan J, Gupta RC. Bovine milk-derived exosomes for drug delivery. Cancer Lett. 2016;371(1):48–61.View ArticleGoogle Scholar
  91. Srivastava A, Babu A, Filant J, Moxley KM, Ruskin R, Dhanasekaran D, et al. Exploitation of exosomes as Nanocarriers for gene-, chemo-, and immune-therapy of Cancer. J Biomed Nanotechnol. 2016;12(6):1159–73.PubMedView ArticlePubMed CentralGoogle Scholar
  92. Wang J, Zheng Y, Zhao M. Exosome-based cancer therapy: implication for targeting cancer stem cells. Front Pharmacol. 2016;7:533.PubMedPubMed CentralGoogle Scholar
  93. Kawikova I, Askenase PW. Diagnostic and therapeutic potentials of exosomes in CNS diseases. Brain Res. 2015;1617:63–71.PubMedView ArticlePubMed CentralGoogle Scholar
  94. Li X, Tsibouklis J, Weng T, Zhang B, Yin G, Feng G, et al. Nano carriers for drug transport across the blood-brain barrier. J Drug Target. 2017;25(1):17–28.PubMedView ArticlePubMed CentralGoogle Scholar
  95. Shimbo K, Miyaki S, Ishitobi H, Kato Y, Kubo T, Shimose S, et al. Exosome-formed synthetic microRNA-143 is transferred to osteosarcoma cells and inhibits their migration. Biochem Biophys Res Commun. 2014;445(2):381–7.PubMedView ArticlePubMed CentralGoogle Scholar
  96. Lou G, Song X, Yang F, Wu S, Wang J, Chen Z, et al. Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma. J Hematol Oncol. 2015;8:122.PubMedPubMed CentralView ArticleGoogle Scholar
  97. Munoz JL, Bliss SA, Greco SJ, Ramkissoon SH, Ligon KL, Rameshwar P. Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma Multiforme cells conferred Chemosensitivity. Mol Ther Nucleic Acids. 2013;2:e126.PubMedPubMed CentralView ArticleGoogle Scholar
  98. Zhang Y, Li L, Yu J, Zhu D, Zhang Y, Li X, et al. Microvesicle-mediated delivery of transforming growth factor beta1 siRNA for the suppression of tumor growth in mice. Biomaterials. 2014;35(14):4390–400.PubMedView ArticlePubMed CentralGoogle Scholar
  99. Pascucci L, Cocce V, Bonomi A, Ami D, Ceccarelli P, Ciusani E, et al. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. J Control Release. 2014;192:262–70.PubMedView ArticlePubMed CentralGoogle Scholar
  100. Kim MS, Haney MJ, Zhao Y, Mahajan V, Deygen I, Klyachko NL, et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine. 2016;12(3):655–64.View ArticleGoogle Scholar
  101. Saari H, Lazaro-Ibanez E, Viitala T, Vuorimaa-Laukkanen E, Siljander P, Yliperttula M. Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells. J Control Release. 2015;220(Pt B):727–37.PubMedView ArticlePubMed CentralGoogle Scholar
  102. Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med. 2005;3(1):9.PubMedPubMed CentralView ArticleGoogle Scholar
  103. Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology. 2016;5(4):e1071008.PubMedView ArticlePubMed CentralGoogle Scholar
  104. Chun-Zhi Z, Lei H, An-Ling Z, Yan-Chao F, Xiao Y, Guang-Xiu W, et al. MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer. 2010;10:367.PubMedPubMed CentralView ArticleGoogle Scholar
  105. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell. 2009;16(6):498–509.PubMedPubMed CentralView ArticleGoogle Scholar
  106. Zhong S, Li W, Chen Z, Xu J, Zhao J. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. Gene. 2013;531(1):8–14.PubMedView ArticlePubMed CentralGoogle Scholar
  107. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem. 2008;283(44):29897–903.PubMedPubMed CentralView ArticleGoogle Scholar
  108. Chen WX, Liu XM, Lv MM, Chen L, Zhao JH, Zhong SL, et al. Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs. PLoS One. 2014;9(4):e95240.PubMedPubMed CentralView ArticleGoogle Scholar
  109. Chen CF, He X, Arslan AD, Mo YY, Reinhold WC, Pommier Y, et al. Novel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase IIalpha and drug responsiveness. Mol Pharmacol. 2011;79(4):735–41.PubMedPubMed CentralView ArticleGoogle Scholar
  110. Lucotti S, Rainaldi G, Evangelista M, Rizzo M. Fludarabine treatment favors the retention of miR-485-3p by prostate cancer cells: implications for survival. Mol Cancer. 2013;12(1):52.PubMedPubMed CentralView ArticleGoogle Scholar
  111. Vergani E, Di Guardo L, Dugo M, Rigoletto S, Tragni G, Ruggeri R, et al. Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. Oncotarget. 2016;7(4):4428–41.PubMedView ArticleGoogle Scholar
  112. Li X, Liu X, Xu W, Zhou P, Gao P, Jiang S, et al. C-MYC-regulated miR-23a/24-2/27a cluster promotes mammary carcinoma cell invasion and hepatic metastasis by targeting Sprouty2. J Biol Chem. 2013;288(25):18121–33.PubMedPubMed CentralView ArticleGoogle Scholar
  113. Akao Y, Nakagawa Y, Hirata I, Iio A, Itoh T, Kojima K, et al. Role of anti-oncomirs miR-143 and -145 in human colorectal tumors. Cancer Gene Ther. 2010;17(6):398–408.PubMedView ArticleGoogle Scholar
  114. Akao Y, Nakagawa Y, Kitade Y, Kinoshita T, Naoe T. Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci. 2007;98(12):1914–20.PubMedView ArticleGoogle Scholar
  115. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A. 2009;106(9):3207–12.PubMedPubMed CentralView ArticleGoogle Scholar
  116. Takagi T, Iio A, Nakagawa Y, Naoe T, Tanigawa N, Akao Y. Decreased expression of microRNA-143 and -145 in human gastric cancers. Oncology. 2009;77(1):12–21.PubMedView ArticleGoogle Scholar
  117. Akao Y, Noguchi S, Iio A, Kojima K, Takagi T, Naoe T. Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett. 2011;300(2):197–204.PubMedView ArticleGoogle Scholar
  118. Corcoran C, Rani S, O'Driscoll L. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. Prostate. 2014;74(13):1320–34.PubMedView ArticleGoogle Scholar
  119. Siemens H, Jackstadt R, Kaller M, Hermeking H. Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget. 2013;4(9):1399–415.PubMedPubMed CentralView ArticleGoogle Scholar
  120. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A. 2008;105(10):3903–8.PubMedPubMed CentralView ArticleGoogle Scholar
  121. Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen AW, et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res. 2010;16(2):430–41.PubMedPubMed CentralView ArticleGoogle Scholar
  122. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004;64(11):3753–6.PubMedView ArticlePubMed CentralGoogle Scholar
  123. Jaiswal R, Luk F, Gong J, Mathys JM, Grau GE, Bebawy M. Microparticle conferred microRNA profiles--implications in the transfer and dominance of cancer traits. Mol Cancer. 2012;11:37.PubMedPubMed CentralView ArticleGoogle Scholar
  124. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005;102(39):13944–9.PubMedPubMed CentralView ArticleGoogle Scholar
  125. Takeshita F, Patrawala L, Osaki M, Takahashi RU, Yamamoto Y, Kosaka N, et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther. 2010;18(1):181–7.PubMedView ArticlePubMed CentralGoogle Scholar

Copyright

© The Author(s). 2019

Advertisement